Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 9, n. 6, p. s604, 2025. DOI: 10.25251/2ddr5090. Disponível em: https://skin.dermsquared.com/skin/article/view/3883. Acesso em: 23 jan. 2026.